Biotech Values

[Praveen]

The initial data in HCV was good enough I felt. But as I mentioned my main focus was always Promune and Actilon is always a second fiddle. After the Null pt population data in Nov 06, I lost confidence and took a loss in one of my accounts. It stings but better at this stage to drop rather than pushing further.

I am more disappointed with Coley mgmt that they were not very aggressive in other indications being the first in space and having such a big IP estate.

Regards,
Praveen